Leads Biolabs' opamtistomig wins Japan orphan status for EP-NEC

Leads Biolabs has secured Orphan Drug Designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for opamtistomig, its PD-L1/4-1BB bispecific antibody, in the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). The Hong Kong-listed company said the designation marks opamtistomig's third ODD globally, following equivalent grants from the US FDA and the European Commission.

The MHLW designation unlocks a standard package of Japanese regulatory incentives, including financial support for clinical development, access to priority consultation pathways, potential fee reductions, and an extended re-examination period after marketing authorisation. Leads Biolabs said it intends to use these incentives to accelerate both EP-NEC development and subsequent submissions across other tumour types in Japan.

Regulatory momentum

Opamtistomig has accumulated a substantial stack of regulatory recognitions over the past two years. China's National Medical Products Administration (NMPA) granted it Breakthrough Therapy Designation in October 2024 and awarded priority review to its New Drug Application in July 2026; that NDA was accepted and entered technical review in August 2026. The FDA added Fast Track Designation in January 2026, alongside the European Commission ODD granted in the same month.

Charles Cai, Chief Medical Officer of Leads Biolabs, said the Japanese designation "underscores the innovative value and global development potential of opamtistomig, particularly in EP-NEC, a tumour type with substantial unmet medical needs."

The company describes opamtistomig as an "IO 2.0" backbone candidate. Mechanistically, it simultaneously blocks PD-1/PD-L1 immune suppression while conditionally activating 4-1BB, a co-stimulatory receptor whose agonism can reactivate exhausted T cells. Leads Biolabs says the conditional activation design yields a safety profile broadly comparable to existing PD-1/PD-L1 inhibitors, a longstanding challenge that has limited earlier 4-1BB agonist programmes from other developers. Clinical data in EP-NEC, NSCLC, and biliary tract cancer have been presented at ASCO, WCLC, and ESMO.

Market and competitive context

Japan represents the world's fourth-largest pharmaceutical market, with an estimated value of over $73 billion in 2025, of which the immuno-oncology segment alone accounted for more than $8 billion. Securing ODD there provides Leads Biolabs with a structured entry point into a market that has historically favoured established Western and domestic Japanese biologics players.

The broader 4-1BB agonist space has been marked by setbacks: earlier unconditional 4-1BB agonists from larger developers were constrained by hepatotoxicity signals at efficacious doses. Leads Biolabs' conditional activation approach, built on its proprietary X-Body bispecific platform, is positioned as a technical resolution to that problem, though the pivotal registrational data needed to confirm durable overall survival benefit across its seven claimed tumour types are still maturing. The company is running one pivotal single-arm study and one confirmatory Phase 3 trial, with nine further proof-of-concept studies ongoing across 14 indications in total.

If the NMPA approves opamtistomig following its NDA review, Leads Biolabs says it would represent the world's first approved 4-1BB-targeting antibody and the first approved treatment specifically for EP-NEC, a rare and aggressive malignancy with limited current options. Investors will be watching NMPA timelines closely; Chinese priority review typically targets a review period of around six months, placing a potential decision in the first half of 2027.